Bausch & Lomb Corp (BLCO)

$17.10 -0.01 (-0.06%)
Market Cap 6.11B
Revenue (ttm) 5.10B
Net Income (ttm) -360.00M
EPS (ttm) N/A
PE Ratio 26.40
Forward PE 20.86
Profit Margin -7.06%
Debt to Equity Ratio 0.79
Volume 322,300
Avg Vol 469,900
Day's Range N/A - N/A
Shares Out 357.04M
Stochastic %K 83%
Beta 0.56
Analysts Sell
Price Target $18.08

Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeut...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 905 695 7700
Address:
520 Applewood Crescent, Vaughan, Canada
DidYouReadThis
DidYouReadThis Jul. 7 at 6:50 PM
$OTLK vs $BLCO, How many years do you think it might take $OTLK to have a higher market cap than $BLCO? Good luck to $OTLK for PDUFA 7/29/26 #WetAMD #Bevacizumab! Bausch + Lomb Corp market cap about 6.13B. Outlook Therapeutics market cap: about 226.61 million.
0 · Reply
Coolhat1
Coolhat1 Jul. 2 at 11:32 PM
$BLCO someday
1 · Reply
Coolhat1
Coolhat1 Jul. 2 at 3:15 PM
$BHC $BLCO going up
0 · Reply
Coolhat1
Coolhat1 Jun. 29 at 8:47 PM
$BHC if anyone has a brain at $COO they would merge with $BLCO and hire Brent as ceo to take over and have him sell it for a large premium. Look at what he did with forest lab allergen and actavis. Merged all of them
1 · Reply
TickrTalk0007
TickrTalk0007 Jun. 15 at 3:39 AM
$BLCO worthless company with sh*tty products. Fire the BD and Corp strategy team
0 · Reply
TraderJoe65
TraderJoe65 Jun. 10 at 2:58 AM
$LENZ in what world does $BLCO not buy this outright
2 · Reply
Aldinho_lbk
Aldinho_lbk May. 28 at 2:43 PM
$OTLK the fact institutional investors are on board after learning FDA approval towards "final labeling", directors have more skin in the game, and Baush and Lomb $BLCO is the potential candidate according to Claude AI, makes this stock a preferred investment for this upcoming month.
0 · Reply
CgI86
CgI86 May. 28 at 6:49 AM
$BHC $BLCO $COO
0 · Reply
Aldinho_lbk
Aldinho_lbk May. 27 at 8:25 PM
$OTLK according to Claude, the likelihood of institutions acquiring $OTLK shares in the open market are higher because "undervalue". Baush and Lomb $BLCO may be the partnership needed.
0 · Reply
Aldinho_lbk
Aldinho_lbk May. 26 at 4:15 PM
$OTLK people taking a sip on speculative take over, with Roche $RHHBY as potential candidate. Allow me to differ. ALCON $ALC and Baush Lamb $BLCO are more suitable partners here in the USA, even for a M&A...
1 · Reply
Latest News on BLCO
Bausch + Lomb price target raised to $21 from $19 at Citi

2026-07-08T10:15:21.000Z - 43 minutes ago

Bausch + Lomb price target raised to $21 from $19 at Citi

Bausch + Lomb price target raised to $17 from $16 at Evercore ISI

2026-07-06T12:46:45.000Z - 1 day ago

Bausch + Lomb price target raised to $17 from $16 at Evercore ISI

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

Jul 6, 2026, 7:15 AM EDT - 1 day ago

Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29

Bausch + Lomb announces new findings from third State of Dry Eye survey

2026-07-01T11:11:48.000Z - 6 days ago

Bausch + Lomb announces new findings from third State of Dry Eye survey

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Jul 1, 2026, 7:00 AM EDT - 6 days ago

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 1:20 PM EDT - 4 weeks ago

Bausch + Lomb Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Bausch + Lomb Transcript: R&D Day 2026

Jun 1, 2026, 1:00 PM EDT - 5 weeks ago

Bausch + Lomb Transcript: R&D Day 2026

Bausch + Lomb Slides: FY 2026

Jun 1, 2026, 1:00 PM EDT - 5 weeks ago

Bausch + Lomb Slides: FY 2026

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

Jun 1, 2026, 6:59 AM EDT - 5 weeks ago

Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 21, 2026, 7:15 AM EDT - 6 weeks ago

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

May 20, 2026, 4:49 PM EDT - 6 weeks ago

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

Bausch + Lomb Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 6 weeks ago

Bausch + Lomb Transcript: AGM 2026

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

2026-05-19T11:10:10.000Z - 7 weeks ago

Bausch + Lomb announces U.S. launch of PreserVision AREDS3

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

2026-05-07T14:16:04.000Z - 2 months ago

Bausch + Lomb launches Bi-Blade+ dual-port vitrectomy cutter in Europe

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

May 6, 2026, 7:15 AM EDT - 2 months ago

Bausch + Lomb Announces Second R&D “Teach-in” Webinar

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

2026-04-30T16:45:33.000Z - 2 months ago

Bausch + Lomb price target lowered to $16 from $17 at Evercore ISI

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

2026-04-30T14:24:47.000Z - 2 months ago

Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

2026-04-30T11:48:27.000Z - 2 months ago

Bausch + Lomb price target lowered to C$19 from C$21 at Citi

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Apr 30, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Bausch + Lomb Earnings Call Transcript: Q1 2026

Bausch + Lomb Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Bausch + Lomb Earnings release: Q1 2026

Bausch + Lomb Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Bausch + Lomb Slides: Q1 2026

Bausch + Lomb Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Bausch + Lomb Quarterly report: Q1 2026

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

2026-04-29T11:55:45.000Z - 2 months ago

Bausch + Lomb reports Q1 adjusted EPS 5c, consensus 5c

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

2026-04-29T11:51:53.000Z - 2 months ago

Bausch + Lomb raises FY26 revenue view to $5.420B-$5.530B from $5.375B-$5.475B

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Apr 29, 2026, 6:58 AM EDT - 2 months ago

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Bausch + Lomb announces narrative review on certain B vitamins

2026-04-23T11:15:36.000Z - 2 months ago

Bausch + Lomb announces narrative review on certain B vitamins

Bausch + Lomb Releases 2025 Sustainability Impact Report

Apr 22, 2026, 7:15 AM EDT - 2 months ago

Bausch + Lomb Releases 2025 Sustainability Impact Report

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

2026-04-16T11:23:23.000Z - 2 months ago

Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Apr 16, 2026, 7:00 AM EDT - 2 months ago

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

Bausch + Lomb Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Bausch + Lomb Proxy statement: Proxy filing

Bausch + Lomb receives FDA 510k clearance for Bi-Blade+

2026-04-08T11:16:31.000Z - 3 months ago

Bausch + Lomb receives FDA 510k clearance for Bi-Blade+

Bausch + Lomb announces European availability of enVista Envy lenses

2026-04-07T11:29:47.000Z - 3 months ago

Bausch + Lomb announces European availability of enVista Envy lenses

Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI

2026-04-06T12:24:21.000Z - 3 months ago

Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Apr 6, 2026, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Mar 30, 2026, 7:15 AM EDT - 3 months ago

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

Bausch + Lomb Transcript: Status update

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Transcript: Status update

Bausch + Lomb Press release: Status update

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Press release: Status update

Bausch + Lomb Slides: Status update

Mar 23, 2026, 1:30 PM EDT - 3 months ago

Bausch + Lomb Slides: Status update

Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma

2026-03-23T11:05:32.000Z - 3 months ago

Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Mar 23, 2026, 7:00 AM EDT - 3 months ago

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Mar 13, 2026, 9:00 AM EDT - 4 months ago

Bausch + Lomb Corporation Investigated by the Portnoy Law Firm

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Mar 9, 2026, 7:15 AM EDT - 4 months ago

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds

2026-02-25T15:05:56.000Z - 4 months ago

Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds

BAC C COST FDX GS GT IBM

L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports

2026-02-24T21:00:27.000Z - 4 months ago

L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports

COST FDX GT

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Feb 24, 2026, 7:00 AM EST - 4 months ago

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright

2026-02-23T13:32:50.000Z - 4 months ago

Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright

Bausch + Lomb price target raised to $15 from $13 at BofA

2026-02-19T14:06:13.000Z - 4 months ago

Bausch + Lomb price target raised to $15 from $13 at BofA

BHC

Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank

2026-02-19T12:35:34.000Z - 4 months ago

Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank

Bausch + Lomb Earnings Call Transcript: Q4 2025

Feb 18, 2026, 8:00 AM EST - 4 months ago

Bausch + Lomb Earnings Call Transcript: Q4 2025

DidYouReadThis
DidYouReadThis Jul. 7 at 6:50 PM
$OTLK vs $BLCO, How many years do you think it might take $OTLK to have a higher market cap than $BLCO? Good luck to $OTLK for PDUFA 7/29/26 #WetAMD #Bevacizumab! Bausch + Lomb Corp market cap about 6.13B. Outlook Therapeutics market cap: about 226.61 million.
0 · Reply
Coolhat1
Coolhat1 Jul. 2 at 11:32 PM
$BLCO someday
1 · Reply
Coolhat1
Coolhat1 Jul. 2 at 3:15 PM
$BHC $BLCO going up
0 · Reply
Coolhat1
Coolhat1 Jun. 29 at 8:47 PM
$BHC if anyone has a brain at $COO they would merge with $BLCO and hire Brent as ceo to take over and have him sell it for a large premium. Look at what he did with forest lab allergen and actavis. Merged all of them
1 · Reply
TickrTalk0007
TickrTalk0007 Jun. 15 at 3:39 AM
$BLCO worthless company with sh*tty products. Fire the BD and Corp strategy team
0 · Reply
TraderJoe65
TraderJoe65 Jun. 10 at 2:58 AM
$LENZ in what world does $BLCO not buy this outright
2 · Reply
Aldinho_lbk
Aldinho_lbk May. 28 at 2:43 PM
$OTLK the fact institutional investors are on board after learning FDA approval towards "final labeling", directors have more skin in the game, and Baush and Lomb $BLCO is the potential candidate according to Claude AI, makes this stock a preferred investment for this upcoming month.
0 · Reply
CgI86
CgI86 May. 28 at 6:49 AM
$BHC $BLCO $COO
0 · Reply
Aldinho_lbk
Aldinho_lbk May. 27 at 8:25 PM
$OTLK according to Claude, the likelihood of institutions acquiring $OTLK shares in the open market are higher because "undervalue". Baush and Lomb $BLCO may be the partnership needed.
0 · Reply
Aldinho_lbk
Aldinho_lbk May. 26 at 4:15 PM
$OTLK people taking a sip on speculative take over, with Roche $RHHBY as potential candidate. Allow me to differ. ALCON $ALC and Baush Lamb $BLCO are more suitable partners here in the USA, even for a M&A...
1 · Reply
NVDAMillionaire
NVDAMillionaire May. 13 at 8:29 PM
$BLCO Great piece that accurately captures BLCO's current position. So if you want to refresh your understanding of BLCO or learn about BLCO for the first time, this is essential reading. https://everyticker.com/quote/BLCO/analysis/margin-inflection-meets-portfolio-diversification-at-bausch-lomb-nyse-blco
0 · Reply
Stock_Spectator
Stock_Spectator May. 13 at 4:08 AM
$BLCO - so much for another Tuesday….
1 · Reply
Davidhansraj
Davidhansraj May. 7 at 12:51 AM
$BLCO oh don’t torture him his prediction was full of heart
0 · Reply
Stock_Spectator
Stock_Spectator May. 5 at 2:39 PM
$BLCO maybe this Tuesday? Oh, right, that’s today…..
0 · Reply
PenkeInvesting
PenkeInvesting Apr. 30 at 7:26 PM
Fundamental analysis of $BLCO (Bausch & Lomb Corp) based on financial data and reported results. #BLCO
0 · Reply
Stock_Spectator
Stock_Spectator Apr. 29 at 2:08 PM
$BLCO earnings call was an easy short. Then will drive $BHC to financial ruin.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 1:16 PM
$BLCO Q1 '26 Earnings Results & Recap Bausch + Lomb raised its full-year 2026 revenue guidance to $5.420B-$5.520B, with 5.3-7.2% constant currency growth, and adjusted EBITDA excluding acquired IPR&D to $1.010B-$1.060B.
0 · Reply
Stock_Spectator
Stock_Spectator Apr. 28 at 11:48 AM
$BLCO it’s Tuesday again. The only announcement will be another huge quarterly loss and unmanageable debt pile.
1 · Reply
Axos300
Axos300 Apr. 27 at 1:40 PM
$BLCO They have to come up with 10 billion in 2027. 2.5 billion of which is due February 17th 2027. Bankruptcy is in their future.
1 · Reply
Stock_Spectator
Stock_Spectator Apr. 23 at 5:30 PM
$BLCO maybe back to the $10 range and then $BHC is out of financing options.
0 · Reply
Stock_Spectator
Stock_Spectator Apr. 23 at 4:51 PM
$BLCO once the short side drives this low enough, the whole house of cards falls apart with $BHC forced into bankruptcy
0 · Reply
Stock_Spectator
Stock_Spectator Apr. 22 at 3:16 PM
$BLCO so you were shorting into your acquisition assertions ?
0 · Reply